Globus Medical Inc (GMED) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate robust growth, debt‑free positioning, and strategic expansion that strengthen Globus’s competitive edge in spine and neuromodulation markets.

Key Takeaways

• Revenue hit $2.52 B, up 61% YoY
• Non‑GAAP EPS reached $3.04, 31% increase
• Free cash flow $405 M, 145% growth
• Debt‑free target Q1 2025 after $1 B repayment
• Acquired Nevro for $250 M, adding musculoskeletal portfolio

Pulse Analysis

Globus Medical closed 2024 with a record $2.519 billion in revenue, a 61 percent jump from the prior year, driven by strong spine implant sales and the full integration of NuVasive. Non‑GAAP earnings per share climbed to $3.04, up 31 percent, while free cash flow surged to $405 million, a 145 percent increase. The cash generation enabled the company to retire the remaining $1 billion of merger‑related debt, positioning Globus to be debt‑free by the end of the first quarter of 2025. These results underscore the effectiveness of cost‑synergy initiatives and disciplined capital allocation.

Innovation remained a cornerstone of the year, with 18 new products launched, including five in the fourth quarter alone. Enabling technologies such as the Cortex MIS system, Allegiance retractor, and the ExcelsiusFlex robotic navigation platform expanded the company’s minimally invasive portfolio and drove a 44 percent rise in enabling‑tech revenue to $47 million. Robotic procedures grew 17 percent, surpassing 94,000 cases since launch, and the ExcelsiusHub and E3D imaging suite cemented Globus’s leadership in integrated navigation solutions. This pipeline of advanced devices reinforces market share gains across the U.S. and international spine markets.

Strategically, Globus announced a $250 million cash acquisition of Nevro Corporation, adding high‑frequency neuromodulation technology and an estimated $2 billion addressable market. The deal broadens the company’s musculoskeletal footprint, creating cross‑selling opportunities between spinal implants and neuromodulation therapies. Integration plans leverage Globus’s scale and sales force to accelerate Nevro’s market penetration while the combined R&D platform aims to translate high‑frequency technology into next‑generation spinal solutions. Together with ongoing synergy capture and a target adjusted gross margin of 68 percent in 2025, the acquisition positions Globus for sustained top‑line growth and enhanced shareholder returns.